MicroRNA-124-3p inhibits cell migration and invasion in bladder cancer cells by targeting ROCK1

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Xu, Xianglai ^a   Li, Shiqi ^a   Lin, Yiwei ^a   Chen, Hong ^a   Hu, Zhenghui ^a   Mao, Yeqing ^a   Xu, Xin ^a   Wu, Jian ^a   Zhu, Yi ^a   Zheng, Xiangyi ^a   Luo, Jindan ^a   Xie, Liping ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Bladder cancer; Invasion; Migration; miR 124 3p; ROCK1

Indexed keywords

GELATINASE A; GELATINASE B; MICRORNA 124; MICRORNA 124-3P; RHO ASSOCIATED COILED COIL CONTAINING PROTEIN KINASE 1; RHO KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER INHIBITION; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; MIGRATION INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; DNA PRIMERS; FLOW CYTOMETRY; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; URINARY BLADDER NEOPLASMS;

EID: 84886739633     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-276     Document Type: Article

References (46)

1. Kakehi Y, Hirao Y, Kim WJ, Ozono S, Masumori N, Miyanaga N, Nasu Y, Yokomizo A. Bladder cancer working group report. Jpn J Clin Oncol 2010, 40(Suppl 1):i57-64.
2. Kim WJ, Bae SC. Molecular biomarkers in urothelial bladder cancer. Cancer Sci 2008, 99:646-652. 10.1111/j.1349-7006.2008.00735.x, 18377416.
3. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005, 66:4-34.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
5. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233. 10.1016/j.cell.2009.01.002, 3794896, 19167326.
6. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10:704-714. 10.1038/nrg2634, 3467096, 19763153.
7. Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 2009, 69:4851-4860. 10.1158/0008-5472.CAN-08-4043, 19487295.
8. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 2009, 125:345-352. 10.1002/ijc.24390, 19378336.
9. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 2011, 59:671-681. 10.1016/j.eururo.2011.01.044, 21296484.
10. Puerta-Gil P, Garcia-Baquero R, Jia AY, Ocana S, Alvarez-Mugica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava F, Sanchez-Carbayo M. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 2012, 180:1808-1815. 10.1016/j.ajpath.2012.01.034, 22426337.
11. Rosenberg E, Baniel J, Spector Y, Faerman A, Meiri E, Aharonov R, Margel D, Goren Y, Nativ O. Predicting progression of bladder urothelial carcinoma using microRNA expression. BJU Int 2013, 112(7):1027-1034.
12. Guo L, Sun B, Sang F, Wang W, Lu Z. Haplotype distribution and evolutionary pattern of miR-17 and miR-124 families based on population analysis. PLoS One 2009, 4:e7944. 10.1371/journal.pone.0007944, 2775919, 19956752.
13. Cao X, Pfaff SL, Gage FH. A functional study of miR-124 in the developing neural tube. Genes Dev 2007, 21:531-536. 10.1101/gad.1519207, 1820895, 17344415.
14. Xia H, Cheung WK, Ng SS, Jiang X, Jiang S, Sze J, Leung GK, Lu G, Chan DT, Bian XW, et al. Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cells. J Biol Chem 2012, 287:9962-9971. 10.1074/jbc.M111.332627, 3322968, 22253443.
15. Hunt S, Jones AV, Hinsley EE, Whawell SA, Lambert DW. MicroRNA-124 suppresses oral squamous cell carcinoma motility by targeting ITGB1. FEBS Lett 2011, 585:187-192. 10.1016/j.febslet.2010.11.038, 21112327.
16. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010, 31:766-776. 10.1093/carcin/bgp250, 19843643.
17. Liang YJ, Wang QY, Zhou CX, Yin QQ, He M, Yu XT, Cao DX, Chen GQ, He JR, Zhao Q. MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis 2013, 34:713-722. 10.1093/carcin/bgs383, 3581604, 23250910.
18. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, Martin-Subero JI, Cordeu L, Garate L, San Jose-Eneriz E, Abizanda G, Rodriguez-Otero P, Fortes P, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 2009, 69:4443-4453. 10.1158/0008-5472.CAN-08-4025, 19435910.
19. Shimizu T, Suzuki H, Nojima M, Kitamura H, Yamamoto E, Maruyama R, Ashida M, Hatahira T, Kai M, Masumori N. Methylation of a panel of MicroRNA genes is a novel biomarker for detection of bladder cancer. Eur Urol 2012, 63(6):1091-1100.
20. Ishizaki T, Naito M, Fujisawa K, Maekawa M, Watanabe N, Saito Y, Narumiya S. p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett 1997, 404:118-124. 10.1016/S0014-5793(97)00107-5, 9119047.
21. Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 2009, 28:65-76. 10.1007/s10555-008-9170-7, 19160018.
22. Xie X, Peng J, Chang X, Huang K, Huang J, Wang S, Shen X, Liu P, Huang H. Activation of RhoA/ROCK regulates NF-kappaB signaling pathway in experimental diabetic nephropathy. Mol Cell Endocrinol 2013, 369:86-97. 10.1016/j.mce.2013.01.007, 23376009.
23. Choi HJ, Han JS. Overexpression of phospholipase D enhances Bcl-2 expression by activating STAT3 through independent activation of ERK and p38MAPK in HeLa cells. Biochim Biophys Acta 1823, 2012:1082-1091.
24. Deng G, Kakar S, Kim YS. MicroRNA-124a and microRNA-34b/c are frequently methylated in all histological types of colorectal cancer and polyps, and in the adjacent normal mucosa. Oncol Lett 2011, 2:175-180. 3412539, 22870149.
25. Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 2009, 69:8742-8751. 10.1158/0008-5472.CAN-09-1541, 19887617.
26. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003, 4:446-456. 10.1038/nrm1128, 12778124.
27. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y, Oshima H. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003, 9:2632-2641.
28. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454. 10.1038/nrc822, 12189386.
29. Guarino M. Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol 2007, 39:2153-2160. 10.1016/j.biocel.2007.07.011, 17825600.
30. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000, 2:76-83. 10.1038/35000025, 10655586.
31. Cheng H-L, Trink B, Tzai T-S, Liu H-S, Chan S-H, Ho C-L, Sidransky D, Chow N-H. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 2002, 20:1544-1550. 10.1200/JCO.20.6.1544, 11896103.
32. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003, 4:915-925. 10.1038/nrm1261, 14685170.
33. Baek J-H, Birchmeier C, Zenke M, Hieronymus T. The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity. J Immunol 2012, 189:1699-1707. 10.4049/jimmunol.1200729, 22802413.
34. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 2000, 148:779-790. 10.1083/jcb.148.4.779, 2169367, 10684258.
35. Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB, Wilson S, Koul HK. p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res 2010, 70:832-841. 10.1158/0008-5472.CAN-09-2918, 20068172.
36. Dodd T, Jadhav R, Wiggins L, Stewart J, Smith E, Russell JC, Rocic P. MMPs 2 and 9 are essential for coronary collateral growth and are prominently regulated by p38 MAPK. J Mol Cell Cardiol 2011, 51:1015-1025. 10.1016/j.yjmcc.2011.08.012, 3208797, 21884701.
37. Dai R, Li J, Fu J, Chen Y, Wang R, Zhao X, Luo T, Zhu J, Ren Y, Cao J, et al. The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells. J Biol Chem 2012, 287:39812-39823. 10.1074/jbc.M112.406520, 23024367.
38. Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012, 61:278-289. 10.1136/gut.2011.239145, 21672940.
39. Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, Filetti S. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation?. BMC Cancer 2002, 2:35. 10.1186/1471-2407-2-35, 139985, 12475396.
40. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, Xiong Q, Wang B, Li XC, Xie K. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001, 61:4143-4154.
41. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, Xie K. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004, 10:4109-4117. 10.1158/1078-0432.CCR-03-0628, 15217947.
42. Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 2000, 60:1546-1551.
43. Venkov C, Plieth D, Ni T, Karmaker A, Bian A, George AL, Neilson EG. Transcriptional networks in epithelial-mesenchymal transition. PLoS One 2011, 6:e25354. 10.1371/journal.pone.0025354, 3184133, 21980432.
44. Choi J, Park SY, Joo CK. Transforming growth factor-beta1 represses E-cadherin production via slug expression in lens epithelial cells. Invest Ophthalmol Vis Sci 2007, 48:2708-2718. 10.1167/iovs.06-0639, 17525203.
45. Zhang X, Li Y, Dai C, Yang J, Mundel P, Liu Y. Sp1 and Sp3 transcription factors synergistically regulate HGF receptor gene expression in kidney. Am J Physiol Renal Physiol 2003, 284:F82-94.
46. Guan H, Cai J, Zhang N, Wu J, Yuan J, Li J, Li M. Sp1 is upregulated in human glioma, promotes MMP-2-mediated cell invasion and predicts poor clinical outcome. Int J Cancer 2012, 130:593-601. 10.1002/ijc.26049, 21469139.